Longchuan Bai

发表

Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2012, Journal of Mammary Gland Biology and Neoplasia.

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2018, Journal of medicinal chemistry.

Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment

Shaomeng Wang, Shi-Yong Sun, S. Qiu, 2011, Molecular Cancer Therapeutics.

Sumoylation-dependent Control of Homotypic and Heterotypic Synergy by the Krüppel-type Zinc Finger Protein ZBP-89*

J. Iñiguez-Lluhí, J. Merchant, Holly N. Brevig, 2007, Journal of Biological Chemistry.

Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.

J. Merchant, D. J. Law, J. Kao, 2006, Gastroenterology.

Regulation of epithelial cell growth by ZBP-89

J. Merchant, C. Logsdon, Longchuan Bai, 2002, International journal of gastrointestinal cancer.

Helicobacter pylori-secreted factors inhibit dendritic cell IL-12 secretion: a mechanism of ineffective host defense.

J. Merchant, J. Kao, Sivaprakash Rathinavelu, 2006, American journal of physiology. Gastrointestinal and liver physiology.

Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases.

Shaomeng Wang, Chao-yie Yang, Z. Nikolovska-Coleska, 2009, Journal of medicinal chemistry.

Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2011, Journal of medicinal chemistry.

Design of Small‐Molecule Peptidic and Nonpeptidic Smac Mimetics

Shaomeng Wang, Chao-yie Yang, Z. Nikolovska-Coleska, 2009 .

LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.

Shaomeng Wang, Chao-yie Yang, D. McEachern, 2012, Cancer research.

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis

Shaomeng Wang, Shi-Yong Sun, Weilong Yao, 2022, Neoplasia.

Therapeutics , Targets , and Chemical Biology LRIG 1 Modulates Cancer Cell Sensitivity to Smac Mimetics by Regulating TNF a Expression and Receptor Tyrosine Kinase Signaling

Shaomeng Wang, Chao-yie Yang, D. McEachern, 2012 .

338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2014 .

Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases.

Shaomeng Wang, Chao-yie Yang, Z. Nikolovska-Coleska, 2008, Journal of medicinal chemistry.

A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.

Liu Liu, Shaomeng Wang, J. Stuckey, 2013, Journal of medicinal chemistry.

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Shanghai Yu, Liu Liu, Wei Sun, 2014, Cancer research.

Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.

Liu Liu, Shaomeng Wang, J. Stuckey, 2015, Journal of medicinal chemistry.

Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.

Liu Liu, Chao-Yie Yang, Liu Liu, 2012, Journal of medicinal chemistry.

Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

Liu Liu, Shaomeng Wang, J. Stuckey, 2017, Journal of medicinal chemistry.

Small-molecule SMAC mimetics as new cancer therapeutics.

Shaomeng Wang, Longchuan Bai, David Smith, 2014, Pharmacology & therapeutics.

SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.

Shaomeng Wang, Yi Sun, Z. Nikolovska-Coleska, 2008, Cancer research.

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.

Liu Liu, Shaomeng Wang, J. Stuckey, 2019, Cancer cell.

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo

Liu Liu, Shaomeng Wang, D. McEachern, 2014, PloS one.

Topography of transcriptionally active chromatin in glioblastoma

H. Wakimoto, T. Tan, Shaomeng Wang, 2021, Science Advances.

Reduced Pepsin A Processing of Sonic Hedgehog in Parietal Cells Precedes Gastric Atrophy and Transformation*

J. Merchant, A. Todisco, L. Samuelson, 2007, Journal of Biological Chemistry.

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

Liu Liu, Shaomeng Wang, J. Stuckey, 2018, Journal of Medicinal Chemistry.

Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12‐O‐tetradecanoylphorbol‐ 13‐acetate–induced ornithine decarboxylase (ODC) activity by retinoids: A potential role for trans‐RA–induced ZBP‐89 in ODC inhibition

J. Merchant, M. Dawson, L. Jong, 2001, International journal of cancer.

Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.

Shaomeng Wang, C. Qin, Longchuan Bai, 2019, Drug discovery today. Technologies.

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Liu Liu, Shaomeng Wang, D. McEachern, 2017, Journal of medicinal chemistry.

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.

M. Ellis, Shunqiang Li, Liu Liu, 2017, Cancer research.

Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

Z. Nikolovska-Coleska, Jianyong Chen, D. Bernard, 2010, ACS medicinal chemistry letters.

Gli1 Deletion Prevents Helicobacter-Induced Gastric Metaplasia and Expansion of Myeloid Cell Subsets

J. Merchant, J. Kao, L. Bai, 2013, PloS one.

ZBP-89, Sp1, and Nuclear Factor-κB Regulate Epithelial Neutrophil-activating Peptide-78 Gene Expression in Caco-2 Human Colonic Epithelial Cells*

J. Merchant, D. J. Law, T. Wang, 2001, The Journal of Biological Chemistry.

Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases

Shaomeng Wang, Hua Li, T. Lawrence, 2011, Molecular Cancer Therapeutics.

Design of small-molecule peptidic and nonpeptidic Smac mimetics.

Su Qiu, Jianfeng Lu, Shaomeng Wang, 2008, Accounts of chemical research.

Transcription Factor ZBP-89 Cooperates with Histone Acetyltransferase p300 during Butyrate Activation of p21 waf1 Transcription in Human Cells*

J. Merchant, Longchuan Bai, 2000, The Journal of Biological Chemistry.

ZBP-89 Promotes Growth Arrest through Stabilization of p53

J. Merchant, Longchuan Bai, 2001, Molecular and Cellular Biology.

MCL-1 inhibition in cancer treatment

Weiguo Xiang, Longchuan Bai, Chao-Yie Yang, 2018, OncoTargets and therapy.

Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.

Liu Liu, Shaomeng Wang, Dajun Yang, 2020, Journal of medicinal chemistry.

Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.

James Delproposto, J. Stuckey, Krishnapriya Chinnaswamy, 2016, ACS medicinal chemistry letters.

Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2012, Journal of medicinal chemistry.

ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate.

J. Merchant, Longchuan Bai, 2007, Biochemical and biophysical research communications.

P53 mutants suppress ZBP-89 function.

J. Merchant, Morihiro Okada, A. Tessier, 2006, Anticancer research.

Transcription factor ZBP-89 is required for STAT1 constitutive expression.

J. Merchant, Longchuan Bai, 2003, Nucleic acids research.

ZBP-89 mediates butyrate regulation of gene expression.

J. Merchant, Morihiro Okada, L. Bai, 2003, The Journal of nutrition.

A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion

J. Merchant, Longchuan Bai, 2007, FEBS letters.

Targeting apoptosis pathways for new cancer therapeutics.

Shaomeng Wang, Longchuan Bai, 2014, Annual review of medicine.

Nutritional Genomics in Cancer Processes ZBP-89 Mediates Butyrate Regulation of Gene Expression 1 , 2

J. Merchant, Morihiro Okada, L. Bai, 2003 .

Structure-Based Discovery of SD-36 as a Potent, Selective and Efficacious PROTAC Degrader of STAT3 Protein.

Liu Liu, Shaomeng Wang, J. Stuckey, 2019, Journal of medicinal chemistry.

Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors.

Shaomeng Wang, Z. Nikolovska-Coleska, Jianyong Chen, 2009, Bioorganic & medicinal chemistry letters.

Molecular dynamics simulation of site-directed mutagenesis of HIV-1 Tattrans-activator

L. Ling, Runsheng Chen, B. Qiang, 1999 .

Design, Synthesis, and Biological Evaluation of Apcin-Based CDC20 Inhibitors.

F. Park, Wei Li, R. Bhuniya, 2022, ACS medicinal chemistry letters.

Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.

Shaomeng Wang, J. Stuckey, D. McEachern, 2023, Journal of medicinal chemistry.

A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo

Wei Jiang, J. Stuckey, D. McEachern, 2023, Nature Chemical Biology.

SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.

Shaomeng Wang, J. Stuckey, D. McEachern, 2021, ACS medicinal chemistry letters.

Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

Liu Liu, Shaomeng Wang, J. Stuckey, 2012, Journal of medicinal chemistry.

Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.

Liu Liu, Shaomeng Wang, Xueliang Fang, 2012, Journal of medicinal chemistry.